Sebelipase alfa

Drug Profile

Sebelipase alfa

Alternative Names: Kanuma; Lysosomal acid lipase - Synageva BioPharma; Recombinant human lysosomal acid lipase - Synageva BioPharma; Recombinant lysosomal acid lipase - Synageva BioPharma; rhLAL - Synageva BioPharma; rLAL; SBC-102

Latest Information Update: 07 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Synageva BioPharma
  • Developer Alexion Pharmaceuticals
  • Class Carboxylic ester hydrolases; Proteins
  • Mechanism of Action Sterol esterase replacements; Sterol esterase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wolman disease; Cholesterol ester storage disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholesterol ester storage disease; Wolman disease

Most Recent Events

  • 16 Feb 2017 Alexion Pharmaceuticals has a patent protection for Sebelipase alfa in Europe until 2021
  • 11 Nov 2016 Additional long term safety and efficacy data from the phase III ARISE trial in Cholesterol ester storage disease presented at the Liver Meeting 2016, the annual meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 06 Oct 2016 Positive long-term efficacy data from the phase III ARISE trial in Cholesterol ester storage disease released by Alexion pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top